title: ÐÐ½Ð³Ð¸Ð±Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ Ð¸ Ð½Ð°ÑÐµÐ»Ð¸Ð²Ð°Ð½Ð¸Ðµ Ð½Ð° ÑÐ°ÐºÐ¾Ð²ÑÐµ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑÐ¾Ð¼ Ð½Ð°Ð½Ð¾Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ð° â Ð°Ð½ÑÐ¸ÑÐµÐ»Ð¾ (AMC)
title: Inhibition and targeting to cancer stem cells by the nanoliposome â antibody complex (AMC)
Creators: name: Ð¥Ð¾ ÐÐ¸Ð½Ñ ÐÑÑÑ
name: Ð¤ÑÐ½Ð³ Ð¢Ñ Ð¸ ÐÐ¸Ð¼ Ð¥ÑÑ
name: "ÐÑÐµÐ´Ð¼Ð°Ð³Ð¸ÑÑÐµÑÑÐºÐ°Ñ Ð¿Ð¾Ð´Ð³Ð¾ÑÐ¾Ð²ÐºÐ° Ð¸Ð½Ð¾ÑÑÑÐ°Ð½Ð½ÑÑ  Ð³ÑÐ°Ð¶Ð´Ð°Ð½ Ð² Ð²ÑÐ·Ð°Ñ  Ð Ð¾ÑÑÐ¸Ð¸", Ð¼ÐµÐ¶Ð²ÑÐ·Ð¾Ð²ÑÐºÐ°Ñ Ð½Ð°ÑÑÐ½Ð¾-Ð¿ÑÐ°ÐºÑÐ¸ÑÐµÑÐºÐ°Ñ Ð¾Ð½Ð»Ð°Ð¹Ð½-ÐºÐ¾Ð½ÑÐµÑÐµÐ½ÑÐ¸Ñ (4; 2022; Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³)
Publisher: name: ÐÐÐÐÐ¢ÐÐ¥-ÐÐ ÐÐ¡Ð¡
Year: 2023
Subjects: Ð½Ð°Ð½Ð¾Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ñ
ÑÐ°ÐºÐ¾Ð²ÑÐµ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸
Ð´Ð¾ÑÑÐ°Ð²ÐºÐ° Ð»ÐµÐºÐ°ÑÑÑÐ²
ÑÐ°ÑÐ³ÐµÑÐ¸Ð½Ð³
Ð»ÐµÑÐµÐ½Ð¸Ðµ ÑÐ°ÐºÐ°
nano liposomes
cancer stem cells
drug delivery
targeting
cancer treatment

description: Ð¦ÐµÐ»ÐµÐ½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ðµ Ð»ÐµÑÐµÐ½Ð¸Ðµ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÑÐ¾ÑÑÐ´Ð¾Ð² ÑÐ²Ð»ÑÐµÑÑÑ ÑÐ»Ð¾Ð¶Ð½ÑÐ¼ Ð°ÑÐ¿ÐµÐºÑÐ¾Ð¼ Ð² ÑÐ¾Ð²ÑÐµÐ¼ÐµÐ½Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ ÑÐ°ÐºÐ°. Ð Ð´Ð°Ð½Ð½Ð¾Ð¼ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ð¸ Ð°Ð²ÑÐ¾ÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð»Ð¸ Ð½Ð°Ð½Ð¾Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ñ ÐºÐ°Ðº ÑÐ¸ÑÑÐµÐ¼Ñ Ð´Ð¾ÑÑÐ°Ð²ÐºÐ¸ Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð². ÐÐ»Ñ Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ñ Ð½Ð°Ð½Ð¾ÑÑÑÐ¿ÐµÐ½Ð·Ð¸Ð¸ Ð°Ð²ÑÐ¾ÑÑ Ð¸Ð·Ð²Ð»ÐµÐºÐ°Ð»Ð¸ Ð°Ð½Ð°ÐºÐ°ÑÐ´Ð¸ÐµÐ²ÑÑ ÐºÐ¸ÑÐ»Ð¾ÑÑ (AA) Ð¸Ð· Ð¾Ð±Ð¾Ð»Ð¾ÑÐµÐº Ð¾ÑÐµÑÐ¾Ð² ÐºÐµÑÑÑ. ÐÐ°Ð½Ð¾Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ñ Ð¸Ð¼ÐµÑÑ Ð¼Ð°Ð»ÐµÐ½ÑÐºÐ¸Ð¹ ÑÐ°Ð·Ð¼ÐµÑ, ÑÑÐ¾ Ð¾Ð±Ð»ÐµÐ³ÑÐ°ÐµÑ Ð¸Ñ ÑÑÐ²Ð¾ÑÐµÐ¼Ð¾ÑÑÑ, Ð° ÑÐ°ÐºÐ¶Ðµ ÑÐ½Ð¸Ð¶Ð°ÐµÑ ÑÐ¾ÐºÑÐ¸ÑÐ½Ð¾ÑÑÑ, ÑÐ²ÐµÐ»Ð¸ÑÐ¸Ð²Ð°ÐµÑ Ð¸Ñ Ð±Ð¸Ð¾Ð´Ð¾ÑÑÑÐ¿Ð½Ð¾ÑÑÑ Ð¸ ÑÐ¼ÐµÐ½ÑÑÐ°ÐµÑ ÑÑÐµÐ±ÑÐµÐ¼ÑÑ Ð´Ð¾Ð·Ñ. ÐÐ²ÑÐ¾ÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð»Ð¸ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÐµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð° (mAbs) Ð´Ð»Ñ ÑÑÐ¸Ð»ÐµÐ½Ð¸Ñ Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²Ð¾Ð³Ð¾ ÑÑÑÐµÐºÑÐ° AA. mAbs ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸ ÑÐ²ÑÐ·ÑÐ²Ð°ÑÑÑÑ Ñ Ð¼Ð°ÑÐºÐµÑÐ°Ð¼Ð¸ ÑÐ°ÐºÐ¾Ð²ÑÑ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº (CSCs), Ð¾Ð±ÑÐ°Ð·ÑÑ ÑÐµÐ»ÐµÐ²Ð¾Ð¹ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑ, ÐºÐ¾ÑÐ¾ÑÑÐ¹ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÑÐµÑ CSCs. Ð­ÑÐ¾Ñ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑ, Ð½Ð°Ð·Ð²Ð°Ð½Ð½ÑÐ¹ Ð½Ð°Ð½Ð¾Ð°Ð½Ð°ÐºÐ°ÑÐ´Ð¸ÐµÐ²ÑÐ¼, ÑÐ²Ð»ÑÐµÑÑÑ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÐ¼ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð¾ (AMC), ÐºÐ¾ÑÐ¾ÑÐ¾Ðµ Ð¸Ð·ÑÑÐ°ÐµÑÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÑÑÑÑÐ¾Ð¹ÑÑÐ²Ð° DLS, ÑÑÐ¾ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ Ð¾ÑÐµÐ½Ð¸ÑÑ ÐµÐ³Ð¾ ÑÐ°Ð·Ð¼ÐµÑ ÐºÐ°Ðº Ð¿ÑÐ¸Ð¼ÐµÑÐ½Ð¾ 99,08 Ð½Ð¼, PDI 0,228 Ð¸ Ð½ÐµÐ¹ÑÑÐ°Ð»ÑÐ½ÑÐ¹ Ð·ÐµÑ-Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð» -9,38 Ð¼Ð. ÐÑÐ¸ ÑÐ¾ÑÐµÑÐ°Ð½Ð¸Ð¸ Ñ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÐ¼ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð¾Ð¼ mAb^CD133 Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐ¹ AMC Ð¿ÑÐ¾ÑÐ²Ð»ÑÐµÑ ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð½ÑÑ ÑÐ¿Ð¾ÑÐ¾Ð±Ð½Ð¾ÑÑÑ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾Ð²Ð°ÑÑ ÑÐ°ÐºÐ¾Ð²ÑÐµ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸ NTERA-2, Ñ IC50 = 299,79 Â± 13,39 Ð¼ÐºÐ Ð¿Ð¾ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ Ñ AA-DMSO. ÐÑÐ¾Ð¼Ðµ ÑÐ¾Ð³Ð¾, AMC Ð¸Ð¼ÐµÐµÑ Ð¾ÑÐµÐ½Ñ Ð½Ð¸Ð·ÐºÑÑ ÑÐºÐ¾ÑÐ¾ÑÑÑ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº (8,04%), Ð² ÑÐ¾ Ð²ÑÐµÐ¼Ñ ÐºÐ°Ðº Ð¾Ð±ÑÐ°Ð·ÐµÑ AA-DMSO Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÑÐµÑ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸ Ð´Ð¾ 48,27%, Ð½ÐµÑÐ¼Ð¾ÑÑÑ Ð½Ð° Ð²ÑÑÐ¾ÐºÐ¸Ðµ ÑÑÐ¾Ð²Ð½Ð¸ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ NTERA-2. Ð­ÑÐ¸ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÑÑÑ Ð¿ÑÐµÐ²Ð¾ÑÑÐ¾Ð´ÑÑÐ²Ð¾ ÑÐµÐ»ÐµÐ½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÑÑÑÐµÐ³Ð¾ ÑÑÑÐµÐºÑÐ° AMC Ð½Ð°Ð´ Ð´ÑÑÐ³Ð¸Ð¼Ð¸ Ð¾Ð±ÑÐ°Ð·ÑÐ°Ð¼Ð¸.
description: Targeting tumor blood vessels is a critical aspect of current cancer therapies. This study employed nanoliposomes as a delivery system for anticancer drugs, specifically focusing on Anacardic Acid (AA) isolated from cashew nut shells, which is combined with a nanoemulsion complex to form nanosuspensions. Nanoliposomes have small sizes, making them easily absorbed and reducing toxicity, while increasing their bioavailability and decreasing the required dosage. Monoclonal antibodies (mAbs) were also utilized to enhance the antitumor effect of AA. The mAbs bind specifically to cancer stem cell markers (CSCs), forming a target complex that inhibits CSCs. This complex, named the nanoanacardial complex â monoclonal antibody (AMC), was characterized using a DLS device and showed a size of about 99,08 nm, a PDI of 0,228, and a neutral zeta potential of -9,38 mV. When combined with the monoclonal antibody mAb^CD133, the resulting AMC demonstrated increased ability to inhibit NTERA-2 cancer stem cells, with IC50 = 299,79 Â± 13,39 Î¼M, compared to AA-DMSO, which showed a significant difference through millet (p &lt; 0,05). Additionally, the AMS had a very low rate of inhibition of healthy cells (8,04%), while the AA-DMSO sample inhibited healthy cells up to 48,27%, despite inhibiting high levels of NTERA-2. These results demonstrate that the inhibitory effect of AMC on the target direction is superior to that of other samples.